Medication info
Nexrica Capsule 75mg (Pregabalin)

Nexrica Capsule 75mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Nexpharm Korea Co., Ltd.
Appearance
A hard capsule with a reddish-brown top and white bottom, containing white powder that is white or light yellow in color.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201603623 · Approved 2016.06.20 · Insurance code 662503660

Summary

Main use
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of epilepsy (partial-onset seizures)
Who takes it
Adults · Children
Adult dose
This medicine is administered orally, with or without food, in two divided doses of the total daily dose of pregabalin. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: The recommended starting dose is 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central Neuropathic Pain Adults: The recommended starting dose is 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: The recommended starting dose is 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Starting dose (mg/day) Maximum dose (mg/day) TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the administration regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Administration is not recommended in children under 12 years of age or adolescent patients aged 12 to 17 years because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Nexpharm Korea Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of epilepsy (partial-onset seizures)

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • secondary general symptoms
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used in adults for the treatment of peripheral and central neuropathic pain. It is also used as an adjunctive treatment for partial seizures in epilepsy patients, whether they have secondary general symptoms or not. Additionally, it is utilized in the treatment of fibromyalgia.

How to take

Adult dose

This medicine is administered orally, with or without food, in two divided doses of the total daily dose of pregabalin. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: The recommended starting dose is 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central Neuropathic Pain Adults: The recommended starting dose is 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: The recommended starting dose is 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Starting dose (mg/day) Maximum dose (mg/day) TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the administration regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Administration is not recommended in children under 12 years of age or adolescent patients aged 12 to 17 years because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so it is important to closely monitor for changes in mood, abnormal behavior, or symptoms of depression while taking it. Patients with allergies to any of the ingredients or specific genetic disorders, such as lactose intolerance, should not use this medication. Diabetic patients should be cautious as weight gain may require adjustments in the dosage of blood sugar control medications. If adverse reactions such as angioedema occur, stop taking the medication immediately and monitor for swelling around the face or mouth. Elderly patients should be especially cautious in the early stages of use due to the risk of falls from dizziness or drowsiness. Temporary blurred vision or changes in vision may occur, and any abnormal symptoms should be consulted with a doctor. Sudden discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headaches, or anxiety, so dosage should be gradually reduced according to a doctor's instructions. There is a risk of drug abuse, so caution is needed for those with a history of mental illness or drug abuse. Patients with compromised kidney function may require dosage adjustments. Patients with heart disease should be cautious of the potential for congestive heart failure. Co-administration with opioid analgesics poses a risk of central nervous system depression, so special care should be taken when using them together. This medication may cause dizziness and drowsiness, so driving or operating dangerous machinery should be avoided until the effects are confirmed after taking the medication. In early pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant should consult a doctor before use and should use effective contraception. While breastfeeding, this medication may pass into breast milk, so it is necessary to discuss with a doctor whether to stop breastfeeding or discontinue the medication. Overdose may manifest symptoms such as confusion, drowsiness, and depression, and may require treatments such as hemodialysis if necessary. Keep out of reach of children, and it is safer not to transfer to another container. If serious adverse symptoms such as skin rash, fever, or breathing difficulties occur during use, stop taking the medication immediately and inform healthcare professionals.

Side effects

suicidal impulses, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, depression, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, anorexia, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, paraphilia, restlessness, anxiety, mood fluctuations, emotional downturn, emotional lift, difficulty in finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, inability to restrain, apathy, dizziness, drowsiness, ataxia, motor coordination abnormalities, balance disorders, amnesia, attention deficit, memory impairment, tremors, speech disturbances, sensory abnormalities, sensory loss, sedation, hypersomnia, cognitive impairment, nystagmus, language disorders, myoclonus, diminished reflexes, motor abnormalities, psychomotor agitation, positional vertigo, hypersensitivity, burning sensation, action tremors, syncope, confusion, psychomotor retardation, olfactory abnormalities, taste loss, writing disabilities, blurred vision, diplopia, indirect vision loss, visual impairment, visual field loss, photophobia, dry eyes, eyelid swelling, decreased vision, eye pain, eye fatigue, increased lacrimation, ocular irritation, mydriasis, vibration-induced depth perception changes, strabismus, brightness of vision, vertigo, hypersensitivity to sound, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, flatulence, hypersalivation, gastroesophageal reflux disease, oral sensory impairment, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, joint pain, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness, rhabdomyolysis, urination disorders, incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, breast enlargement, peripheral edema, edema, gait disturbances, falling, feeling drunk, altered sensations, fatigue, tightness in the chest, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue edema, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, malaise, delirium, paralysis (facial paralysis), affective disorders, agitation, restlessness, worsening of seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it is important to store it in a tightly sealed container. Additionally, to maintain its effectiveness, it should be stored at a cool temperature between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown top and white bottom, containing white powder that is white or light yellow in color.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.